trending Market Intelligence /marketintelligence/en/news-insights/trending/63mC4yLcG8fThLFw5WxwGQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

SIGA Technologies seeks US FDA approval for smallpox treatment

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

SIGA Technologies seeks US FDA approval for smallpox treatment

SIGA Technologies Inc. submitted a new drug application to the U.S. Food and Drug Administration for its smallpox treatment Tpoxx.

Tpoxx was developed to treat smallpox, as well as other orthopoxvirus infections. There is no cure or treatment approved for smallpox.

SIGA has requested an expedited review of its application. The advanced development of Tpoxx is funded by the U.S. government's Biomedical Advanced Research and Development Authority.

The drug is administered in oral form and was developed under the U.S. FDA's animal rule in which efficacy endpoints are determined in animal studies, and human clinical studies are conducted to determine the safety and confirm dosing.

SIGA expects a response from the U.S. FDA in February 2018.